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ABSTRACT 
REAGENTS AND TOOLS TO IDENTIFY EPIZOOTIC HEMORRHAGIC DISEASE 
VIRUS-2 
MEGHAN SYRSTAD 
2017 
The purpose of this project was to define monoclonal antibodies against viral 
proteins from Epizootic Hemorrhagic Disease Virus (EHDV) to be used in quality control 
of vaccines produced by an industrial partner, and development of tools to identify 
EHDV.  EHDV is an Orbivirus, which also includes Bluetongue Virus and African Horse 
Sickness, which are all transmitted through arthropod vectors. EHDV causes significant 
morbidity and mortality in white-tailed deer, but has recently been found to infect cattle.  
EHDV recently caused significant outbreaks affecting both the farmed and wild cervid 
industry, however few reagents and tools exist to protect against this disease or define the 
virus in vitro. 
To develop new, efficient reagents that can be used to identify EHDV, we 
identified and tested monoclonal antibodies against two different viral capsid proteins, 
VP2 and VP5.  To do this, predictive algorithms were used to generate immunogenic 
peptides specific for each protein.  Three groups of mice were used, one injected with the 
VP2 peptides, one with the VP5 peptides, and the third with a proprietary marker 
sequence localized to the amino terminus of recombinant proteins produced by the 
industrial partner. After fusion, 192 wells were plated from each fusion. Wells containing 
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growing cells after about sixteen days were screened and positive wells were subcloned. 
This process was repeated twice, and we were left with two hybridoma clones 
recognizing epitopes of VP5 and one of VP2. 
Further testing showed cross reactivity the two VP5 antibodies, so we focused on 
the monoclonal antibodies directed against VP2, line 13-2.  Following generation of 
ascites, utility in recognition of both our partners’ recombinant VP2 protein and native 
VP2 proteins of the virus was confirmed.   In addition, a commercial VP5 antibody 
directed against African Horse Sickness virus also recognized recombinant protein, and 
native EHDV VP5 protein in multiple assays.  Both antibodies reacted by ELISA against 
the native proteins and viral lysate from both EHDV-1 and EHDV-2, although only the 
VP5 antibody showed the ability to recognize viral proteins by Western Blot. Work is 
underway to define the ability of the antibodies to recognize and identify EHDV by IFA.
 1 
INTRODUCTION 
Epizootic hemorrhagic disease virus (EHDV) is a noncontagious disease causing 
virus of the genus Orbivirus transmitted by insect vectors (Savini et al., 2011).  The 
disease affects both wild and domestic ruminants, mainly cervids such as white-tailed 
deer.  EHDV can also affect cattle and sheep, and goats may be susceptible (Savini et al., 
2011).  The virus causes many of the same symptoms and infects similar animal species 
as another common Orbivirus, Bluetongue virus (BTV).  The main difference is that 
BTV infects mostly domestic ruminants, such as sheep, whereas EHDV is more common 
in wild cervids, mainly white-tailed deer.  It is estimated that the mortality rate of EHD in 
wild deer is as high as 46% (Stevens, 2015). The two viruses likely share a common 
insect vector and can co-circulate geographically (Ruder et al., 2012).  Diagnosis for both 
diseases requires virus isolation or the detection of specific viral components, such as 
antigen or nucleic acid (Savini et al., 2011).  There are autogenous vaccines for both 
EHDV and BTV in the United States using inactivated virus antigens.  The autogenous 
vaccines are relatively safe, however their effectiveness is not very strong (McVey & 
MacLachlan, 2015).  More detail into the current diagnostics and vaccines specific to 
EHDV will be discussed in a later section.  EHD is currently considered the most 
important viral disease impacting white tailed deer and therefore surveillance has been 
directed at wildlife populations.  Surveillance methods include virus isolation and PCR-
based diagnostics for clinical submissions, questionnaire-based surveillance, cross-
sectional serology studies of selected wild populations, and outbreak investigations 
(Stallknecht DE., 2004). 
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EHDV is a member of the genus Orbivirus and family Reoviridae (Martínez-
Torrecuadrada et al., 1996).  This genus is characterized by a genome of 10 segments of 
linear ds RNA and are transmitted primarily through arthropod vectors.  The members of 
this genus discussed in this review, BTV and EHDV, are all transmitted by species of 
Culicoides midges giving the diseases a seasonal occurrence based on the climate and 
conditions that favor breeding of the insect vector (MacLachlan & Guthrie, 2010).  
Because of this shared pool of vectors, both viruses also share similar global distribution. 
The research involved in this project was focused on white-tailed deer, but the 
symptoms described here are similar to the signs shown in other affected species. There 
are three clinical forms of EHD in white-tailed deer that have been described: peracute, 
acute, and chronic (Savini et al., 2011).  The peracute form consists of high fever, 
anorexia, weakness, respiratory distress, and severe and rapid edema of the head and 
neck.  Animals usually die rapidly, within 8-36 hours, sometimes with no clinical signs.  
The acute, or classic form consists of the same symptoms as per acute, with the addition 
of hemorrhages in many tissues such as skin, heart, and gastro-intestinal tract.  Animals 
often experience hyperemia of conjunctiva and mucus membranes of the oral cavity.  
Many develop ulcers of the tongue, dental pad, palate, and rumen.  There is also a high 
mortality rate associated with the acute form.  In the chronic form of the disease, animals 
are ill for several weeks but gradually recover.  After recovery, the animal may develop 
breaks or rings in their hooves and might become lame due to growth interruption.  
Ulcers in the rumen can also develop.  The high morbidity and mortality rate among wild 
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ruminants has a large impact on wildlife and the captive cervid industry (Stallknecht DE., 
2004). 
Though the epidemiology of EHDV is not as precisely defined as in other 
Orbivirus species, the global range is predicted to occur between the latitudes 35oS and 
49oN.  This range coincides with the distribution of its midge vector (Savini et al., 2011).  
EHDV has been described on almost every continent, including parts of Asia, Australia, 
Africa, and the Americas, although it has not yet been isolated in Europe (Savini et al., 
2011).  In North America, the disease has been found in areas of western Canada that 
would typically be too far north for its vector (Stallknecht DE., 2004).  It is possible that 
climate change and drought play a role in allowing the viral vector to move north. The 
virus appears sporadically in Canada but appears in a two-to-three-year cycle in endemic 
areas.  Though these cycles are not well understood, herd immunity created by the long-
lived neutralizing antibodies seen in deer that survive infection and fluctuations in vector 
populations due to climate could contribute to this timeline (Stallknecht DE., 2004).   
BTV is the most extensively studied of the Orbivirus species and has many 
similarities to EHDV.  BTV was first described in 18th century southern Africa where the 
disease was introduced when sheep were brought to the area.  Currently, twenty-four 
serotypes of BTV are recognized and the virus has been isolated on every continent, 
except Antarctica (MacLachlan & Guthrie, 2010) . In North America, BTV is usually 
associated with severe morbidity and mortality in sheep and can also affect other 
domestic ruminants, such as cattle (William C. Wilson, 2015). Cattle typically do not 
show signs of disease, but are important to the disease as they act as a reservoir for the 
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virus (Anderson G.A., 1987).  There are multiple commercially available vaccines for 
BTV, including both modified-live and inactivated vaccines (McVey & MacLachlan, 
2015).  Because of the animals infected, BTV has a greater impact on the domestic 
ruminant market, while EHD shows greater morbidity and mortality in wildlife and non-
traditional farmed species.  Correctly diagnosing an outbreak can be difficult because 
BTV and EHDV are clinically indistinguishable in affected species (Stallknecht DE., 
2004).  In 1975, Ibaraki disease was described in cattle as having similar clinical signs to 
BTV, though testing showed antigenic differences between the viruses (Campbell CH., 
1975).  It is now known that Ibaraki disease is a strain of EHDV-2 (Anbalagan & Hause, 
2014).  
There are at least 10 serotypes of EHDV.  Two serotypes of this disease were 
isolated in the United States by 1962.  EHDV-1 was described in 1955 (Shope, 
Macnamara, & Mangold, 1960) and in 1962 EHDV-2 was isolated and shown to be 
serologically distinct from EHDV-1 (Allison A.B., 2009).  In 2006 EHDV-6, which had 
previously only been described in Australia, was isolated from white-tailed deer in 
Indiana and may now also be endemic in the United States (Allison A.B., 2009).  There 
are therefore 3 specific serotypes of interest to the US farmed cervid industry.  
   The primary determinant of serotype in both EHD and BTV is the outer capsid 
protein, VP2.  The other capsid proteins, VP5 and VP7 can also elicit antibody response, 
but these have been found less critical to defining serotype, as they are highly conserved.  
The structure of BTV can be seen in Figure 1.  The localization of the capsid proteins is 
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the same in EHDV.  Since clinical signs of EHD are indistinguishable from BTV in 
cattle, laboratory tests are required to definitively diagnose the virus (Savini et al., 2011). 
EHDV replication is monocyte-dependent, meaning the virus replicates within the 
monocytes (Stallknecht, Howerth, Kellogg, Quist, & Pisell, 1997).  Clinical signs appear 
around 4 days post infection and are most severe by day 7 or 8 (Quist et al., 1997).  
Surviving animals return to normal in one or two weeks, although severely affected deer 
can show signs such as appearing thin and weak for as long as four weeks.  A decrease in 
the number of lymphocytes can be observed in infected deer.  EHD infection is also 
associated with a rise in interferon (IFN) levels, peaking around 6 days post infection 
(Quist et al., 1997).  EHDV infection also leads to the development of neutralizing 
antibodies, usually by day 10 post infection.  The neutralizing determinants for this virus 
are located on the VP2 capsid protein, making this protein an ideal vaccine target. 
Ruminants infected with EHDV can be asymptomatic, making diagnostic tests for 
the virus necessary for accurate disease diagnosis, surveillance, and in support of trade 
(William C. Wilson, 2015).  Currently, diagnosis of EHD is limited to virus isolation, 
serum neutralization, or RT-PCR (Savini et al., 2011).  Each method has its own 
downfalls.  For example, RT-PCR is very sensitive and detects viral RNA with great 
accuracy, however it is not possible to determine if there is infectious virus in the sample 
or not.  It is important to be able to quickly identify what virus is causing a potential 
outbreak in order to proceed with control measures.  The symptoms of EHDV are similar 
to many other diseases such as bluetongue, foot-and-mouth disease, vesicular stomatitis, 
and other foreign animal diseases (Stevens, 2015).  It is critical that an outbreak is 
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accurately diagnosed, as the symptoms could lead to concerns of one of the other similar 
diseases that could have a much greater impact on the animal industry. 
 The first recorded outbreak of EHD in North America occurred in New Jersey in 
1955 (Shope et al., 1960).  Two hundred and thirty-three deer carcasses were found, but it 
is estimated that the number of deaths could have been as high as 500-700 animals.  The 
disease was determined to be the same as a disease in the Southern United States as 
“black tongue.” It was also determined that the disease in New Jersey and the disease in 
the southern states were caused by two different serotypes of the virus.  Investigators 
discovered the disease was not horizontally transferred, but were not able to determine 
the mode of transmission at the time, though insect vectors were suspected.  But probably 
the most suspicious aspect of the outbreak was that there were no additional cases of the 
disease in the following four years (Shope et al., 1960).  
In summer and fall of 2012 an unusually large number of EHD cases were 
reported in the United States, specifically Iowa, Nebraska, and South Dakota (Stevens, 
2015).  One hundred and twenty-nine cases were reported in cattle as well as eight cases 
in bison and sixty-five cases in captive white-tailed deer.  In cattle and bison, the 
morbidity rate was 7.12% and there were four deaths, two in cattle and two in bison.  
White-tailed deer showed a morbidity of 46% and mortality of 42%.  It is likely that high 
temperatures and drought were a factor in the 2012 outbreak (Stevens, 2015).  These 
conditions would force the deer to search for sources of water, leading to deer and cattle 
sharing waterers.  A previous study (Schmidtmann et al., 2011) showed that the eastern 
limit of the midge vector that carries EHDV had an eastern limit defined by the Missouri 
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River.  In the 2012 outbreak, many cases were seen outside this normal range. It cannot 
be said whether the expansion of the virus range is due to an actual expansion of the 
vector range or just amplification of EHDV in existing populations (Stevens, 2015). 
EHDV is considered the most important viral disease impacting white-tailed deer 
and therefore surveillance has been directed at wildlife populations.  Surveillance 
methods include virus isolation and PCR-based diagnostics for clinical submissions, 
questionnaire-based surveillance, cross-sectional serology studies of selected wild 
populations, and outbreak investigations (Stallknecht DE., 2004). 
One way to control a potential outbreak of EHDV is through vaccination.  
Currently, only autogenous vaccines have been produced in the United States (McVey & 
MacLachlan, 2015).  Autogenous vaccines are produced by collecting a sample from a 
dead or sick animal and isolating the virus from that sample to develop a vaccine.  
Because of this, these vaccines are only licensed for use on animals in the herd where the 
virus was collected and in adjacent herds.  Also, these vaccines cannot be produced until 
after an outbreak has already started.  The efficacy of these vaccines is also questioned 
since the vaccine is specific only to the strain of virus used in the autogenous formulation 
(Savini et al., 2011).   
This project was performed in conjunction with an industrial partner currently 
developing subunit vaccines against EHDV to service the needs of the captive cervid 
industry.  The purpose of this project was to identify monoclonal antibodies (mAbs) that 
are highly reactive to the capsid protein VP5 and VP2 proteins for use in vaccine 
development, virus identification, and research use.  VP5 is highly conserved throughout 
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the EHDV serotypes whereas VP2 has some variation between serotypes, making it more 
difficult to use as a vaccine target.  We began by producing mAbs against EHDV-2, since 
that was the serotype responsible for the 2012 outbreak and the serotype shown to infect 
cattle (Stevens, 2015).  The primary target of our industrial partner is to develop initial 
recombinant VP2 and VP5 proteins for use in a potential EHDV vaccine.   The first goal 
of this work was to identify monoclonal antibodies that identify these proteins by ELISA 
and Western Blot.      
The second goal of this project was to define the ability of these research tools to 
define EHDV in vitro for research, and potentially diagnostic, purposes.  As stated earlier 
in this review, there are currently very few options for diagnosing EHD and the ones that 
do exist are difficult and time consuming.  To get any future outbreaks of this disease 
under control quickly, there needs to be a fast and easy way to determine the cause of the 
disease.  The first assay we developed was an enzyme-linked immunosorbent assay 
(ELISA).  This is a technique used to measure the levels of antibody or antigen in a 
sample based on the optical density. This technique can quickly determine if there are 
viral proteins present in a sample that react against the mAbs identified.  To confirm the 
production of functional mAbs we also used Western Blotting and an 
Immunofluorescence Assay (IFA).  A Western Blot uses gel electrophoresis to show the 
ability of the antibodies to bind the denatured viral proteins.  In an IFA, fluorescent 
microscopy is used to visualize the binding of the antibody to virus-infected cells. 
In conclusion, EHDV is a vector-bourne disease that infects ruminants such as 
white-tailed deer and cattle.  The virus is spread via insect vector, a species in the 
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Culicoides genus of midges.  The disease causes a variety of symptoms including fever, 
anorexia, lameness, and oral erosions.  These symptoms are similar to many other animal 
diseases, including Bluetongue Virus.  Because of this, quick and accurate diagnosis in 
the case of an outbreak is crucial to determine course of treatment.  There are currently 
no fully licensed vaccines in the United States for EHDV, only autogenous vaccines 
which are herd-specific and have not been tested for efficacy.  The goal of this project 
was to find mAbs to detect viral capsid proteins, VP2 and VP5, allowing us to use them 
to create more efficient assays for the identification EHDV and to use in the development 
of a vaccine for the virus. 
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Figure 1: Orbivirus Structure (Mertens, 2004) 
 
 
Structure of BTV showing the composition of capsid proteins, which are located the same 
as in EHDV.  The VP2 protein is the main determinant of serotype and it, along with the 
VP5 protein, can elicit an antibody response.    
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MATERIALS AND METHODS 
 
Culture of BHK-21 Cells: 
 BHK-21 (baby hamster kidney) cells obtained from the South Dakota State 
University Animal Disease Research and Diagnostic Lab (SDSU ADRDL) were thawed 
in Dulbecco Modified Eagle Medium (DMEM) (Gibco Life Technologies #11995-065) 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologics #S11550H), 100 
I.U./ml penicillin, and 100 µg/ml streptomycin (Gibco Life Technologies #10378-016).  
Cells were monitored daily and subcultured at a 10X dilution when 80-90% confluent. 
Virus Production: 
 EHDV-1 and EHDV-2 was obtained from the SDSU ADRDL.  BHK-21 cells 
were grown in a T75 flask until 70-80% confluent.  Cells were infected with 0.5 ml of 
virus and 2.5 ml of non-supplemented DMEM and incubated at 37°C for one hour.  The 
virus was then removed and 15 ml of DMEM supplemented as described above was 
added.  Infected cells were incubated at 37°C for three days.  The flask was then freeze-
thawed to lyse the cells and media with cell debris was collected.  Cell debris was 
centrifuged and supernatant was collected.  The viral supernatant was then frozen in 2 ml 
cryovials, with 1 ml of supernatant per tube. 
Plaque Assay: 
 Plaque assay was used to determine the titer of EHDV.  Media was warmed prior 
to starting the assay.  BHK-21 cells were trypsinized, centrifuged, and re-suspended in 
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fresh culture media.  The cells were counted and the cell concentration was adjusted to 
1.5x105 cells/ml.  3 ml of cell suspension was added to each well of 6-well plates, four 
plates were used to determine virus titer.  Virus was serially diluted 10-fold (10-1-10-11) in 
DMEM supplemented with 2% FBS.  Three hundred µl of virus dilution was added to 
each well, with two wells for each dilution.  Two wells were not infected to serve as 
control wells.  Plates were incubated for four hours.  While plates were incubating, 4% 
agarose (Seaplaque, Lonza #50101) was melted and placed in a 45°C water bath.  Shortly 
before the end of the four-hour incubation, 15 ml of agarose was added to 30 ml of pre-
warmed culture medium and stored in 37°C incubator until ready to use.  After four 
hours, non-absorbed virus was removed from the plates and 3 ml of agarose was added to 
each well and allowed to set.  Plates were then incubated at 37°C for four days.  Plates 
were then fixed with 10% Buffered Formalin Phosphate by adding 2 ml of formalin over 
the gel and incubated for 1.5 hours at room temperature.  After that time, formalin was 
removed by pipetting and the gel was carefully removed with a spatula.  2 ml of 0.1% 
Crystal violet solution was added over the cell layer and incubated for 15 minutes at 
room temperature.  Crystal violet was then poured off and the wells were gently washed 
with deionized water.  The wells with a virus dilution creating 30-300 clear plaques were 
counted.  Virus titer was then calculated as follows:  
titer (pfu/ml) = plaque count ÷ 0.3 x virus dilution 
Lysate Production: 
 Viral lysate from EHDV-1 and EHDV-2 was produced using the method found in 
the 1994 article by Blacksell, Lunt, and White (Stuart D. Blacksell, 1994).  BHK-21 cells 
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were infected as described above.  After 3 days of incubation, the cells and debris was 
collected and centrifuged.  The pellet was then re-suspended in 1 ml of PBS and 
transferred to a 1.5 ml centrifuge tube.  The cell debris was washed by centrifugation and 
the PBS was decanted.  100 µl of lysate buffer was added to the pellet and the tube was 
vortexed to homogenize.  Lysate was used at a concentration of 1:40 in ELISA analysis, 
as specified in the methods of the article referenced. 
Vaccination and Cell Fusion: 
 B-cells to be used in the development of antibody-producing hybridomas were 
harvested from BALB/c mice.  To stimulate antigen-specific B-cell production, mice 
were injected with peptides from either the EHDV-2 VP2 or VP5 protein.  The peptides 
were synthesized commercially by Selleckchem, sequences provided by the industrial 
partner are listed in Table 1.  Nine mice were divided into three immunization groups; 
leader sequence, VP2, and VP5.  Injections were prepared by diluting 100µl of each 
peptide in Dulbecco’s phosphate-buffered saline (DPBS) (Hyclone #SH30028.02), 
making a final volume of 0.5ml.  This peptide mixture was then mixed with 0.5ml ISA 
71.  Each of the three mice in the group received 0.2ml via intraperitoneal injection. Five 
injections were given over a nine-week period, with the final booster taking place three 
days before cell fusion.  Blood was collected from the mice ten days after the second 
injection and tested for antibody production via ELISA. On the day of cell fusion, one 
mouse from each group was euthanized and the spleens were collected for B-cell harvest. 
The remaining mice were kept in case the first fusion was unsuccessful.   
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Sp2/0 Cell Culture: 
 Sp2/0-Ag14 fusion partner cells (ATCC cat#CRL-1581) were the myeloma cell 
line used in hybridoma fusion.  Cells were cultured about a month prior to fusion, to 
allow the cells to become well-established.  The cells were cultured in DMEM 
supplemented with 10% FBS and 100 I.U./ml penicillin, and 100 µg/ml streptomycin.  
Cells were monitored daily and subcultured when 80-90% confluent. 
Hybridoma Fusion: 
 The hybridoma fusion procedure was adapted from the 1975 article by Kohler and 
Milstein (Kohler & Milstein, 1975).   
 Prior to starting the fusion process, two 50 ml tubes of DMEM per fusion, PEG 
1500, and fusion media was pre-warmed.  Fusion media was made using DMEM 
supplemented with 10% FBS, 5ml of pen/strep, 10ml HFCS (Hybridoma fusion and 
cloning supplement), and 0.05mM 2-mercaptoethanol.  Three fusions were performed on 
the same day, one from each peptide group; leader sequence, VP2, and VP5.  The spleen 
from the mouse vaccinated with the appropriate peptides was harvested and placed in 
well #1 of a six well plate containing 10 ml of cold wash media (plain DMEM).  
Connective tissue was removed using sterile surgical scissors and forceps.  The spleen 
was then transferred to well #2, containing 5 ml of cold wash media and then washed 
another time in 10 ml of cold wash media in well #3.  The spleen was then cut in half and 
carefully ground with the rubber stopper of a 10ml syringe plunger.  A 70µm cell strainer 
was then placed in well #3 and the remaining connective tissue from the spleen was 
placed on the strainer.  The tissue was again ground with the rubber end of the syringe 
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plunger.  The cell strainer and remaining spleen tissue were discarded in a biohazard 
container. Next, any cell clumps were broken up by pipetting and transferred through a 
70µm cell strainer to a 50ml conical tube labeled with the project name and fusion 
number.  An additional 5 ml of cold media wash was used to remove any remaining cells 
from the six-well plate and transfer to the 50ml tube.   
 Splenocytes and Sp2/0 cells were counted using a hemocytometer.  Splenocytes 
and Sp2/0 cells were then combined in a 50ml conical tube at a 5:1 ratio by adding 
myeloma cells to the spleen cells.  The mixture was washed by centrifugation at 1200rpm 
for five minutes in 20ml of warm DMEM.  The supernatant was removed and the cell 
pellet was dissociated by gently tapping the bottom of the tube.  This wash was repeated 
twice and the media was removed and cell pellet dissociated.  Next 1 ml of warm 
PEG1500 (polyethylene glycol) (Roche #783641) was gradually added over one minute 
by dripping the PEG onto the walls of the tube and allowing it to slide to the bottom 
while swirling the tube gently.  PEG acts as a membrane fusion-inducing agent.  The cell 
mixture was swirled for an additional two minutes before adding 1 ml of warm wash 
media over one minute while swirling the tube.  While continuing to swirl, 3 ml of warm 
wash media was added over three minutes followed by 10 ml of warm wash media over 
one minute.  This fusion mixture was incubated at 37°C for five minutes, followed by a 
five-minute centrifugation.  The supernatant was then removed and the pellet dissociated 
by tapping the bottom of the tube and the cell mixture was re-suspended at a 
concentration of 1x106 Sp2/0 cells/ml.  For each fusion, eight 24-well plates were labeled 
 16 
 
with the fusion number and date.  0.5 ml of the cell suspension was added to each well 
and the plates were incubated at 37°C overnight. 
 The next day 0.5 ml of 2X HAT selection media was added to all the wells and 
incubated at 37°C for 72 hours.  This media is made using DMEM supplemented with ten 
percent FBS, 5ml of pen/strep, 10ml HFCS (Hybridoma Fusion and cloning Supplement) 
(Roche #11363735001), 20ml 50X HAT media supplement (Sigma #H0260-10vl) and 
0.05mM 2-mercaptoethanol (Gibco Biologics #21985-023).  HAT selection media 
contains a combination of hypoxanthine, aminopterin, and thymidine.  Aminopterin is a 
drug that blocks the de novo DNA synthesis pathway, which is necessary for the survival 
of myeloma cells.  Hypoxanthine and thymidine are both necessary in the salvage 
pathway of nucleotide synthesis, which can be utilized by the B cells (Ed Harlow, 1999).  
This media combination eliminates unfused myeloma cells.  Unfused B cells are not 
immortal and die out after a short time, allowing for the selection of only hybridoma 
cells.  Four days after fusion about 50-75% of the selection media was replaced with 1X 
HAT media, made with the same components as the 2X HAT media but using half the 
amount of the 50X HAT supplement.  The plates were incubated at 37°C for another 48 
hours and then 50-70% of the media was replaced with fresh 1X HAT media.  Starting 
six days after fusion, plates were monitored daily for colony growth.  On day sixteen 
after fusion colony growth was visible and were ready for screening. 
Screening: 
 Of the 192 wells per group of fused cells plated on the day of fusion, the leader 
sequence plates had 132 plates with colony growth, VP2 had 158 wells, and VP5 had 126 
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wells.  When the colonies were almost confluent, 100µl of supernatant was used to screen 
for antibody production using an ELISA.  Ninety-six (96)-well plates were coated with 
the peptides diluted in 0.5M carbonate-bicarbonate coating buffer at a concentration of 
1:1000, VP2 peptides and VP5 peptides were each mixed so that all VP2 peptides or VP5 
peptides coated one well.  Fifty µl of the coating mixture was added to each well and the 
plates were incubated at 2-8°C overnight.  The next day, coating material was removed 
and 100µl of blocking solution (Blotto) was added to each well.  Plates were then 
incubated for one hour at room temperature.  After removing the blocking buffer, plates 
were washed three times with wash buffer; made from TBS (tris-buffered saline) 
containing 10% blocking solution (Blotto) and 0.05% Tween 20.  The supernatant 
collected from the 24-well plates was then added to the wells and incubated for 2-3 hours 
at room temperature.  The supernatant was then removed and the plates were washed 
three times with the wash buffer.  Next, 100µl of the secondary antibody, goat anti-mouse 
IgG (Southern Biotech 1037-05), was added at a concentration of 1: 2,000 in wash buffer 
and incubated for another hour at room temperature.  The plates were again washed three 
times before adding 100µl of the TMB (tetramethylbenzidine) substrate (Pierce 
Biotechnology).  The plates were then incubated in the dark at room temperature for 
about ten minutes and the reaction was stopped with 1N H2SO4.  The plates were read 
using the ELISA reader at an absorbance of 450nm. 
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Subcloning: 
 Colonies from the 24-well plates that tested positive for antibody production were 
then subcloned.  This process is designed to dilute cells so that they are plated with about 
1 cell/well, making the antibodies monoclonal.   
 Cells from the positive well were grown to 70-80% confluency in either a twenty-
four or six well plate.  Cells were counted and a cell suspension of about 102-103 cells/ml 
was made.  From this cell suspension, three dilutions were made.  First, 200 cells were 
taken from the original suspension and added to 20 ml of HAT Fusion media, this will 
allow a plating density of about two cells per well.  10 ml of this suspension was then 
added to 10 ml of HAT Fusion media to make a density of 1 cell per well, and finally 10 
ml of the new suspension was added to another 10 ml of HAT Fusion media to make a 
plating density of 0.5 cells per well.  Two-tenths ml of each suspension was added to 32 
wells (4 columns) of a 96-well plate. The plates were then incubated for 8-14 days with 
no media changes.  When cell growth was visible, one or two drops of media was added 
to the wells to ensure a sufficient volume for supernatant collection.  A few days after 
adding media to the wells, wells containing cell growth were screened again.  This 
process was repeated for clones that tested positive after screening, to ensure the final 
clones had originated from a single cell. 
Supernatant Production: 
 Once antibody producing hybridomas had been established the cells were scaled 
up to a T225 culture flask and frozen in nine cryotubes for storage.  One tube was thawed 
for supernatant production.  Since it is ideal to serum free supernatant, the cells needed to 
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be weaned off media supplements.  The supplements were gradually removed from the 
media; HCS first, then FBS, and finally HAT.  Once the cells were growing well in 
unsupplemented DMEM, cells were grown up to two T225 culture flasks.  One flask of 
cells was frozen for storage, the other was used for supernatant production.  Cells in the 
second flask were allowed to grow to the point where cells began to die.  This allows for 
maximum secreted antibody levels in the culture media.  Cells were then collected in a 
50ml conical tube and centrifuged for ten minutes at 1700 rpm.  The supernatant was 
collected in a new 50 ml tube, the centrifugation repeated, and the supernatant was 
transferred to a T75 culture flask for storage.  The flask was labeled with the date, name 
of the cell line, and isotype of the antibody and stored at 4°C until needed. 
Western Blot:  
 Western blotting was used to determine if the antibodies produced by the 
hybridomas were binding to the virus and either VP2 or VP5.  To prepare the samples, 
25µl of the appropriate viral protein or lysate was added to 25µl of loading buffer (950µl 
2x Laemmli Sample Buffer, 50µl 2-Mercaptoethanol).  This mixture was then heated on a 
heat block for five minutes at 99°C to denature the proteins and then placed on ice until 
ready to load onto gel (mini-PROTEAN TGX Gels) (BioRad #456-1044).  The gel was 
opened and secured in the BioRad Mini Protean Electrophoresis Tank which was then 
filled to the appropriate level with 1X Running Buffer. The samples were added to the 
wells of the gel along with the Precision Plus Protein Standards Ladder (BioRad #161-
0373).  The BioRad Power supply was attached to the tank and run at 200V and 115mA 
for 35 minutes. 
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 The gel was removed from the assembly and equilibrated in 1X Transfer Buffer 
for 30 minutes along with the nitrocellulose membrane.  The gel sandwich was then 
assembled as follows; fiber pad, filter paper, gel, nitrocellulose, filter paper, fiber pad.  
The cassette was closed and placed in the electrophoresis tank along with an ice pack and 
stir bar and the tank was filled with cold transfer buffer.  The power pack was then 
attached and run at 100V and 300mA for two hours.  The cassette was then carefully 
disassembled and the nitrocellulose membrane was washed with MilliQ water before 
being put in 1X Pierce Clear Milk Blocking Buffer (Pierce #37587) and shook gently at 
room temperature overnight. 
 The next day, the membrane was washed twice with PBST for 5-10 minutes.  A 
pouch was assembled using a thermal seal plastic pouch, which was sealed to leave one 
side open.  The nitrocellulose membrane and primary antibody was added, bubbles 
carefully removed, and the pouch sealed.  The pouch was incubated at room temperature 
for 1.5-3 hours with gentle shaking.  The pouch was cut open and the antibody poured 
out.  The membrane was then washed twice with PBST (phosphate-buffered saline with 
Tween) followed by one wash with PBS (phosphate-buffered saline) before adding the 
secondary antibody to the membrane in a new pouch and gently shaken for 1-2 hours.  
After another three washes, TMB (1-Step Ultra TMB Blotting Solution) was added to the 
nitrocellulose membrane and shaken for up to 30 minutes while monitoring color 
development so as not to overdevelop.  The reaction was stopped by draining the TMB 
and placing the membrane in dH2O for five minutes.  This wash was repeated twice and 
then the membrane was placed on filter paper to dry. 
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Immunofluorescence Assay: 
 To determine the appropriate detection antibody to use, the isotype of the VP2 13-
2 ascites and commercial VP5 10AE12 was determined following the directions of the 
Pierce® Rapid ELISA Mouse mAb Isotyping Kit (Thermo Scientific #37503).  The 
commercial VP5 antibody was determined to be IgG and the VP2 ascites was IgM.   
BHK cells were grown in a T225 flask and then counted and the cells were 
adjusted to a concentration of 2 x 105 cells per ml. 200ul of the cell suspension was added 
to 96 well plates and grown to about 90% confluency. EHDV-1 was used on one plate 
and EHDV-2 on another starting at a 1:5 dilution followed by 2-fold dilutions down the 
plate.  The last row was left virus-free. The plates were then incubated at 37°C for 36 
hours (Wei et al., 2013).  Ascites and 10AE12 were used as the primary antibody, at 
concentrations of 1:5 and 1:1000 respectively.  One hundred ul of the antibody dilution 
was added to half of each plate, so that each antibody was tested against both virus 
serotypes.  The plates were then incubated at 37°C for 1 hour.  After washing with PBS, 
100ul of   goat anti-mouse FITC (Southern Biotech #1020-02) was used as secondary 
antibody at a concentration of 1:100.  IgG FITC was used against the 10AE12 antibody 
and IgM FITC was used against the ascites.  Plates were then incubated at 37°C for 
another hour and then washed with PBS and examined with a fluorescent microscope.   
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Table 1:  Peptide Sequences 
 
 
Sequences of the peptides produced by Selleckchem and used to vaccinate mice to 
produce an antibody response. 
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RESULTS 
Peptide Prediction: 
 Peptides of interest were generated by our Industry partner, VST/Medgene Labs, 
and provided as sequences to be generated for production and screening of monoclonal 
antibodies.  Firstly, a literature search was conducted to define the existence of 
previously-published monoclonal antibodies specific for either of the two target proteins.   
As a result of this search, no existing VP2 monoclonal antibodies were found, however a 
cross-reactive monoclonal antibody (10AE12) developed against the VP5 protein of 
African Horse Sickness virus was found to be broadly reactive against all Orbiviruses.  
The epitope recognized by the 10AE12 monoclonal antibody was highly conserved 
among EHDV sequences, and was obtained for testing (Professional Veterinary Services 
Inc., FL).   To define additional peptide sequences of interest in the generation of 
monoclonals recognizing VP2 and VP5, online resources were used to predict 
immunogenic epitopes expected to be broadly conserved.  Briefly, Genbank sequences 
corresponding to sequences of EHDV-1, EHDV-2, and EHDV-6 were screened based on 
geographical location of original isolation.  Isolates ranging from 2000-present occurring 
in the United States were aligned and used to compare sequence conservation of the VP2 
and VP5 proteins from EHDV.  The sequence for VP5 was found to be highly conserved 
independent of serotype, whereas the VP2 sequence was found to be conserved within 
serotypes.   VP2 protein sequences were aligned within serotype (EHDV-1, EHDV-2, 
and EHDV-6) and between serotype and used to identify regions of marked sequence 
conservation.   Predicted protein sequences were then analyzed using the IEDB Analysis 
 24 
 
Resource (http://tools.iedb.org/main/bcell/) B cell epitope prediction tool to identify 
contiguous peptides that would be expected to be exposed for recognition in the natural 
protein conformation, as well as expected to be immunogenic (ie highly charged, water 
soluble amino acids).   Based on these analyses, individual peptides corresponding to 
individual peptide epitopes predicted to exist in VP2 and VP5 were chosen for each 
serotype.  These peptides were chosen based on (i) sequence conservation among 
multiple serotypes and (ii) expected immunogenicity.  The VP2-3 peptide in particular 
represents a consensus sequence highly conserved among EHDV-1, EHDV-2, and 
EHDV-6, although it most closely matches the sequence of EHDV-6.   These peptides 
were synthesized commercially as KLH-conjugates for immunization, or as free peptides 
that were then used in screening of monoclonal antibodies.    
Mouse Vaccination: 
 After vaccinating the mouse groups with the appropriate peptides, blood was 
collected from every mouse to screen for antibody production.  There were originally 
three mice in each group, however some mice died during the blood collection.  For each 
surviving mouse, blood serum was tested for reactivity to the individual peptides.  Each 
sample was tested against all five peptides (leader sequence, VP2-1, VP2-2, VP5-1, VP5-
2, VP5-3).  Table 2 shows which peptide each mouse showed reactivity against.  In the 
VP2 group, both mice tested reacted to VP2-2.  The mice in the VP5 group all reacted to 
VP5-2.  The mice were boosted with the peptides again prior to euthanizing one mouse 
from each group for B cell collection. 
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Monoclonal Antibody Production: 
 Monoclonal antibodies (mAbs) were produced by fusing the B cells collected 
from the mouse spleen with Sp2/0 cells.  For each fusion, cells were plated on eight 24-
well plates for a total of 192 wells per fusion.  Table 3 shows how many wells from each 
fusion had cell growth before the first fusion.  The table also shows the clone selections 
made after each round of screening and subcloning.  Due to a shortage of HFCS, many 
positive clones were frozen after the first subclone.  Selected clones were subcloned in an 
alternative media supplement, which was used for the remainder of the selection process.  
After three rounds of screening there were six clones of antibody-producing hybridomas: 
VP2 13-2, VP2 13-3, VP5 6-4, VP5 6-7, VP5 3-5, VP5 3-9.  Since the clones came from 
only three plates (13, 6, and 3) only one clone from each plate was used in further tests, 
since the clones from the same plate are likely identical.  The three selected clones were 
then tested for cross reactivity.  Table 4 shows the results of this ELISA.  The VP2 13-2 
clone responded to the appropriate peptide, although it did not show a strong response 
against the native protein. The VP5 clones, 3-5 and 6-4, reacted to all the peptides tested.  
To determine if the mAbs were reacting to some portion of the peptides, the two clones 
were tested against uncoated wells.  The fact that the clones reacted to the uncoated wells 
lead us to believe the mAbs were reacting to the blocking buffer.  Since the clones were 
not specific to the target protein, they were not further characterized.  To ensure the 
blocking buffer did not interfere with future tests, we switched to a protein free blocking 
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buffer in future ELISA tests.  The VP2 13-2 clone was then outsourced to a vendor for 
ascites production. 
Ascites Testing: 
 Once we received the ascites for the VP2 13-2 mAb, testing was done to 
determine how concentrated the ascites was.  Figure 2 shows the results of this ELISA.  
Since the OD of the ascites against the EHDV-2 viral lysate dropped below 0.1 at a 
concentration of 1: 1,000 we decided the lowest concentration to use in future ELISA 
testing should be 1:500.  The VP2 13-2 ascites was then tested for reactivity against viral 
lysates, VP2 and VP5 native proteins, and the peptides that had previously shown 
reactivity to the antibody (VP2-2).  The 13-2 hybridoma supernatant was used to show 
that the ascites at a concentration of 1:500 has similar results as the direct supernatant.  
The commercial VP5 10AE12 antibody was also tested for comparison.  Figure 3 shows 
the results of this ELISA.  Although the OD readings were lower than in past tests, they 
were consistent among the different antibodies tested and were highest for the appropriate 
wells.  The ascites responded better than the supernatant against the viral lysates and VP2 
protein, and had similar results against the individual peptides.  The commercial VP5 
10AE12 had the highest readings against the VP5 protein and peptide, as expected.  The 
ascites was also tested on a Western Blot.  Figure 4 shows the results of the assay for 
both the 13-2 ascites and the VP5 10AE12 antibody.  The 10AE12 responded well to 
both the EHDV-1 and EHDV-2 lysate as well as the VP5 protein.  This can be seen by 
the bands falling at about 61Kd, which is the size of the VP5 protein.  The ascites did not 
respond as strongly as the 10AE12, since the ascites is not as concentrated as the 
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commercial antibody.  There is a band in the VP2 protein lane at about 116Kd, which is 
the size of the VP2 protein.  These results further confirm that the antibodies are reacting 
to the appropriate viral proteins. Finally, the peptides were tested by ELISA against sheep 
sera from both pre-and post-vaccination with the EHD vaccine developed by Medgene 
Labs.  Unfortunately, all the sera came up negative. 
Immunofluorescence Assay: 
 An immunofluorescence assay (IFA) was run using both the VP5 10AE12 mAb 
and VP2 13-2 ascites.  Figure 5 shows the results of this assay.  The VP5 10AE12 (Figure 
5a) reacted strongly against EHDV-2 but not against EHDV-1.  The VP2 13-2 ascites 
showed slightly stronger reactivity against EHDV-2, but also responded to EHDV-1.  
Although it is good that both mAbs were able to recognize EHDV-2, the reactivity 
against EHDV-1 was different than expected.  VP5 is typically more conserved between 
serotypes, so it would be expected that the VP5 mAb would react to both serotypes and 
the VP2 mAb would be more serotype specific.  The results of the IFA do support the 
results of the other testing done on the VP2 ascites, in which the mAb was able to react to 
both serotypes. 
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Table 2: Mouse Serum ELISA Results 
Mouse ID Leader 
Sequence 
VP2-1 VP2-2 VP5-1 VP5-2 VP5-3 
LS Mouse +      
VP2 red   +    
VP2 blue   +    
VP5 red     +  
VP5 black     +  
VP5 blue     +  
 
Results of the mouse serum ELISA showed which peptides the antibodies were specific 
to.  The peptides that showed an antibody response were VP2-2 and VP5-2. 
 
 
Table 3:  Clone Selection Process 
Peptide Fusion  
Wells 
Screening 1 
Positives 
Screening 2 
Positives 
Screening 3 
Positives 
Selected Clones 
Marker 
 
 
132 
 
 
1, 2, 9, 10, 11, 
17, 18, 25, 26, 
33, 88 
 
 
NA 
 
NA 
 
NA 
VP2 
 
 
 
158 
 
43, 52, 69, 77, 
82, 83, 84, 88, 
100, 110, 127 
 
52-7 
110-13 
110-14 
 
 
 
110-13-2 
110-13-3 
 
13-2 
VP5 
 
 
 
126 
 
7, 8, 87, 88, 
101, 103, 105, 
106, 107 
87-3 
106-5 
7-3 
7-6 
7-6-4 
7-6-7 
7-3-5 
7-3-9 
 
 
6-4 
3-5 
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Table 4:  Cross reactivity ELISA 
Sample 
Tested 
VP2-1 
Peptide 
VP2-2 
Peptide 
VP2 
Protein 
VP5-1 
Peptide 
VP5-2 
Peptide 
VP5-3 
Peptide 
VP5 
Protein 
VP2 13-2 - + - - - - - 
VP 5 3-5 + + + + + + + 
VP5 6-4 + + + + + + + 
VP5 10AE12 - - - + - - + 
Media - - - - - - - 
 
 Table 4 shows the results of the ELISA to predict potential cross-reactivity of the 
responding hybridomas.  VP2 13-2 and VP5 10AE12 responded as expected.  The VP5 
mAbs, 3-5 and 6-4, showed cross reactivity, as they responded to all peptides and 
proteins 
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Figure 2: Ascites concentration ELISA 
 
Concentrations of ascites were tested against wells coated with either EHDV-2 lysate or 
the VP2-2 peptide.  The ascites showed a limited positive response to the peptide even at 
a concentration of 1: 2,000.  The response to the lysate dropped below 0.1 at a 
concentration of 1: 1,000, so 1:500 was determined to be the lowest that could be used in 
future testing. 
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Figure 3:  Ascites Reactivity ELISA 
 
The VP2 13-2 ascites was tested for reactivity against viral lysates, VP2 and VP5 native 
proteins, and the peptides that had previously shown reactivity to the antibody.  The 13-2 
hybridoma supernatant was used to show that the ascites at a concentration of 1:500 gives 
the same or better results than the direct supernatant.  The commercial VP5 10AE12 
antibody was also tested for comparison. 
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Figure 4:  Western Blot Results 
 
  75 Kd 
50 Kd 
4a) Western blot using VP2 
13-2 Ascites.  The VP2 protein 
shows a band at about 116Kd. 
4b) Western blot using VP5 
10AE12.  Bands can be seen 
for both EHDV-1 and 
EHDV-2 lysate along with 
the VP5 protein.  All bands 
fall at about 61Kd.  
     VP5    VP2       EHD-1   EHD-2      Ladder 
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Figure 5: IFA Results 
 5a) VP5 10AE12 
              
EHD-1 100X                                EHD-1 200X                           EHD-1 400X 
       
 EHD-2 100X                            EHD-2 200X                            EHD-2 400X 
                
EHD-2 No Virus 
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 5b) VP2 13-2 Ascites 
          
EHD-1 100X                              EHD-1 200X                               EHD-1 400X 
 
           
EHD-2 100X                               EHD-2 200X                           EHD-2 400X 
 
EHD-2 No Virus 
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DISCUSSION 
 
 The goal of this project was to produce and characterize mAbs against the VP2 
and VP5 capsid proteins of EHDV-2 to be used to identify these viral proteins.  The 
project resulted in the identification of one good mAb against the VP2 protein, line 13-2. 
Although we were able to identify multiple clones of hybridomas against the VP5 
protein, the antibodies were cross reactive and were not further characterized.  Instead, 
the commercial VP5 antibody was used.  In the future, clones that were frozen at the 
beginning of the clone selection process due to the HFCS shortage could be expanded 
and characterized.  There were multiple clones that screened as positive after the first 
screening and were not characterized.  Some of these clones could give us more specific 
antibodies that we could use in the future. 
 We were able to use multiple assays to show that the VP2 mAb was successful, 
including ELISA, Western Blotting, and Immunofluorescence Assay (IFA).  ELISA and 
IFA show the ability of the mAbs to recognize whole, native proteins, whereas Western 
Blotting shows their reactivity to the denatured proteins.  Since we optimized these 
assays for both our mAb and the commercial VP5 antibody, the same conditions will 
hopefully work in the future as diagnostic tests for EHDV-2.  We still need to test these 
assays using deer serum to confirm the practical application.  We also plan to repeat the 
fusion and selection process for the other disease-causing serotypes of the virus, EHDV-1 
and EHDV-6.  We were able to do some work with EHDV-1 already using the antibodies 
we have, although they do not respond as strongly to this serotype. The hope is that, with 
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the antibodies found in this project, we will easily be able to distinguish between EHDV 
and BTV, and possibly even have easy diagnostic tests that are serotype specific for 
EHDV.  We have not tested our antibodies against BTV, but the hope is that our VP2 
mAb would be specific to EHDV and not respond to BTV.  This way the antibody could 
be used to differentiate between the two diseases.  Since the commercially produced VP5 
antibody was originally produced from African Horse Sickness, another Orbivirus, there 
is a good chance it would also react to BTV. As for the VP2 13-2 mAb, we were hoping 
it would be specific to only EHDV-2, but the results suggest it is not serotype specific.  
This means we will not be able to use this antibody to determine the serotype causing an 
outbreak.  
 This project is also a part of a larger project being run by Medgene Labs with the 
goal of developing a licensed vaccine against EHDV in white-tailed deer.  This would be 
the first licensed vaccine in North America for this virus and would be a great step in 
controlling the spread of the virus.   
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